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Suppression of b1,3galactosyltransferase b3Gal-T5 in cancer
cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines
and sialyl-Lewis x on O-glycans
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We investigated the role of b3Gal-T5, a member of the
b1,3galactosyltransferase (b1,3Gal-T) family, in cancer-
associated glycosylation, focusing on the expression of
sialyl-Lewis a (sLea, the epitope of CA19.9 antigen), poly
N-acetyllactosamines, and sialyl-Lewis x (sLex) antigen. A
clone permanently expressing an antisense fragment of
b3Gal-T5 was obtained from the human pancreas adeno-
carcinoma cell line BxPC3 and characterized. Both b1,3Gal-
T activity and sLea expression are dramatically impaired in
the clone. Analysis of the oligosaccharides synthesized in
cells metabolically labelled with tritiated galactose shows
that a relevant amount of radioactivity is associated to
large O-glycans. Endo-b-galactosidase mostly releases Neu-
Aca2-3Galb1-3[Fuca1-4]GlcNAcb1-3Gal and NeuAca2-
3Galb1-3GlcNAcb1-3Gal from such O-glycans of BxPC3
membranes, but GlcNAcb1-3Gal and type 2 chain oligo-
saccharides, including NeuAca2-3Galb1-4[Fuca1-3]Glc-
NAcb1-3Gal, from those of the antisense clone.
Furthermore, BxPC3 cells secrete sLea in the culture media
but not sLex, while antisense clone secretes mostly sLex, and
accumulation of both antigens is prevented by benzyl-
a-GalNAc. These data indicate that b3Gal-T5 suppression
turns synthesis of type 1 chain O-glycans to poly N-ace-
tyllactosamine elongation and termination by sLex. In other
cell lines and clones, b3Gal-T5 transcript, b1,3Gal-T acti-
vity, and sLea antigen are also correlated, but quantitatively
the relative expression ratios are very diﬀerent from cell type
to cell type. We suggest that b3Gal-T5 plays a relevant role
in gastrointestinal and pancreatic tissues counteracting the
glycosylation pattern associated to malignancy, and is
necessary for the synthesis and secretion of CA19.9 antigen,
whose expression still depends on multiple interacting
factors.
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Aberrant glycosylation of glycoproteins and glycolipids is
one of many molecular changes that accompany malignant
transformation [1]. Perhaps the best known glycosylation
change inducing malignancy is enhanced b1,6GlcNAc
branching of N-glycans, leading to poly N-acetyllactos-
amine sequences frequently terminated by the sialyl-Lewis x
(sLex) antigenic determinant [2]. GnT-V activity is mostly
responsible for this as shown by several pieces of evidence
obtained in vitro [3,4], and more recently in vivo [5].
Moreover, several studies indicated that O-glycan biosyn-
thesis is also abnormal in cancer cells [6]. It has been shown
that sLex and poly N-acetyllactosamines are associated with
increased malignancy of lung and colorectal cancers [7,8],
and occur in core 2 and extended core 1 O-glycans in
various cells [9,10]. On the other hand, the role of type 1
chain oligosaccharides in cancer-associated glycosylation is
unclear. Although type 1 chain structures occur on all
glycoconjugate classes, and CA19.9 antigen ) that is the
sLea epitope carried by a mucin backbone [11] ) has been
used as a tumour marker in clinical practice for several
years, little is know about their biosynthesis and differential
expression in cancer. b1,3Gal-T activity was found to be
reduced in colon cancer with respect to the normal mucosa
[12], and in the CACO-2 cell model of intestinal differen-
tiation b1,3Gal-T activity [13] and type 1 chain structures
[14] were reported to increase with the differentiation
process. b3Gal-T52 is the member of the b3Gal-T gene family
that was proposed to be responsible for b1,3Gal-T activity
and type 1 chain synthesis in epithelial cells of the digestive
tract [15]. In a previous paper [16] we reported that b3Gal-
T5 efﬁciently adds b1,3Gal residues to GlcNAcb1-3Galb1-
4GlcNAcb1-R branched chains ofN-glycans, leading to Lea
and sLea synthesis, and preventing poly N-acetyllactos-
amine extension and sLex expression. We also found
that the b3Gal-T5 transcript is downregulated in colon
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adenocarcinomas and is responsible for the differential
glycosylation of carcinoembryonic antigen (CEA) in cancer.
b3GalT-5 has a broad acceptor speciﬁcity in vitro [16,17],
but it has not yet been demonstrated in vivo if it works on
O-glycans that are assumed to be largely expressed in
epithelial cells and to be the more relevant carriers of sLea
epitope inCA19.9mucin. As no othermember of the b3Gal-
T gene family known at present is expressed in epithelial cells
and able to synthesize type 1 chain oligosaccharides, the very
low levels of b3Gal-T5 transcript detectable in colon cancer
specimens pose the question of whether relevant amounts of
type 1 chain O-glycans are formed in cancer cells.
To address these issues, we tried to study the effect of
b3Gal-T5 suppression in the human pancreatic adenocar-
cinoma cell line BxPC3 that expresses low levels of b3Gal-
T5 transcript but well detectable amounts of b1,3Gal-T
activity and sLea, that is presumably carried by O-glycans
and even secreted into the culture medium. To this purpose
we transfected the cells with a b3Gal-T5 cDNA fragment
placed in the antisense orientation under the control of a
strong promoter, and isolated a recombinant clone that
stably expresses high levels of the antisense transcript. We
then measured the b1,3Gal-T activity present in the
antisense clone, as well as the Lewis antigens expressed on
the cell surface or secreted in the culture medium. We also
studied the radioactive sugar chains synthesized in parental
BxPC3 cells and in the recombinant antisense clone upon
metabolic labelling with tritiated Gal, with emphasis on
O-glycans and poly N-acetyllactosamines. We also com-
pared the amount of b3Gal-T5 transcript and b1,3Gal-T
activity with the levels of sLea expressed in other cell lines
and clones.
Experimental procedures
Cell cultures and treatments
COLO-205, HCT-15, CACO-2, HT-29, SW-1116 (from
human colon adenocarcinomas), and MKN-45 (from
human gastric cancer) cells were cultured as described
previously [16,18]. Human pancreatic adenocarcinoma cells
BxPC3 (ATCC CRL-1687) and Panc-1 (ATCC CRL-1469)
were cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% foetal bovine serum, 100 UÆmL)1 penicillin,
1.0 mgÆmL)1 streptomycin and 2 mM L-Glu. For treating
BxPC3 cells and clones with drugs affecting glycosylation,
1 · 105 cells were plated in 12-well plates, incubated for
30 h with regular medium that was replaced with medium
containing 1.0 lgÆmL)1 swainsonine (Sigma) or 2 mM
benzyl-a-GalNAc (Sigma). After growing for 60 h in the
presence of drugs, media were collected again. Media
obtained before and after treatment were centrifuged at
3000 g for 10 min and the clean supernatants were used for
dot-blots.
Cultured cells were harvested, centrifuged, aliquoted, and
freshly processed for ﬂow cytometry as reported [16], or
homogenated for RNA extraction or enzyme assay,
according to the procedures described [18].
Preparation of pSV2Neo, pcDNAI/Fuc-TIII, and
pCDM8/b3Gal-T5 was as reported [16]. Antisense plasmid
pEFneo/ASb3Gal-T5 was constructed by cloning a frag-
ment of b3Gal-T5 cDNA in the antisense orientation in the
vector pEFneo, a generous gift of N. Hiraiwa (Aiki Cancer
Center, Nagoya, Japan). Vector relevant features include
the strong human elongation factor-1a promoter [19], the
linker sequence containing a 358-bp stuffer between two
nonpalindromic BstXI sites, and the simian virus 40 (SV40)
polyadenylation signals. cDNA was obtained from COLO-
205 total RNA and ampliﬁed by PCR with a commercially
available high ﬁdelityTaq polymerase (LATaq, Takara) as
reported [16], using speciﬁc primers as follows. Upper
strand primer: 5¢-GCGCTCTAGACCCAGCGTCTCCA
GCTTGCATGGCC-3¢, having a 4-base ﬁller, an XbaI
restriction site (underlined), and a 25-base sequence corres-
ponding to nucleotides )192 to )160 from the start ATG
codon in the b3Gal-T5 gene. Lower strand primer:
5¢-GCGCAAGCTTGATAATGTCCCCGTGTCGCTG
GCTCTC-3¢, having a 4-base ﬁller, a HindIII site (under-
lined), and a 27-base sequence corresponding to nucleotide
334–360 in the coding region of the gene. PCR reactions
were incubated as follows: 94 C for 3.5 min followed by 25
cycles of 1.5 min at 94 C (melting) and 3.5 min at 72 C
(annealing plus extension), and a ﬁnal extension step at
72 C for 8 min. The ampliﬁed DNA was digested with
XbaI and HindIII, for other purposes, or blunt-ended,
ligated to BstXI adaptors, and cloned into the correspond-
ing sites of pEFneo, using the procedure described [20].
Direct DNA sequencing of the construct obtained, per-
formed by the dideoxynucleotide chain-terminationmethod
using an automated procedure, indicated that the sequence
of the construct obtained, pEFneo/ASb3Gal-T5, was iden-
tical to that expected.
Construction of cell clones
HCT-15 expressing b3Gal-T5, MKN-45 expressing Fuc-
TIII, and BxPC3 expressing antisense b3Gal-T5 construct,
were obtained by the calcium phosphate transfection
method [21], using a modiﬁcation of the procedure [16].
The DNA mixture contained 1.5 lg EcoRI-linearized
pSV2Neo and 20 lg ScaI-linearized pcDNAI/Fuc-TIII, or
1.5 lg EcoRI-linearized pSV2Neo and 20 lg ScaI-linea-
rized pCDM8/b3Gal-T5, or 1.5 lg EcoRI-linearized
pSV2Neo and 20 lg Tth111I-linearized pEFneo/ASb3-
Gal-T5, respectively. Upon selection with 0.4 mgÆmL)1
active G418, colonies were collected using cloning cylinders
and grown in 48-well plates. G418-resistant HCT-15 and
MKN-45 colonies were stained with anti-sLea Ig, analysed
by ﬂuorescence microscopy on tissue culture slides, and
subcloned [16]. G418-resistant BxPC3 colonies were
screened by competitive RT/PCR. Total RNA was extrac-
ted from colonies and reverse transcribed, and cDNA
submitted to PCR ampliﬁcation with human b-actin
primers, for normalization [16,20], or with primers speciﬁc
to the antisense construct. Single colonies expressing a
constant level of sLea, named HCT-15-T5 and MKN-45-
FT, or of antisense b3Gal-T5 construct, named T5AS,
were selected and used for further characterization and
experiments.
Metabolic labelling and carbohydrate analysis
BxPC3 cells and T5AS clone (4.0 · 106 cells) were plated
in 25-mm2 ﬂasks containing 0.2 mCi [3H]Gal (Amersham
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Pharmacia Biotech) in 4.0 mL culture medium and
incubated for 40 h under regular conditions. Labelled cells
were harvested, resuspended in phosphate-buffered saline
at a density of 4 · 107 cellsÆmL)1, and processed according
to published procedures [9,16,22], with some modiﬁca-
tions. Total lysates were obtained by boiling 10 min in
phosphate-buffered saline containing 0.5% SDS and 1.0%
2-mercaptoethanol, and spinning at 12 000 r.p.m. for
10 min. The clean supernatants were made 1% for
Nonidet P40 and 50 mM for sodium phosphate buffer
pH 7.5, and treated with N-glycanase (New England
Biolabs P0704), 50 000 NEB UÆmg)1 cell lysate protein,
for 20 h at 37 C. Lysate protein was 0.8 mgÆmL)1.
Reaction mixtures were passed through a Sephadex G-50
column (0.7 · 50 cm) equilibrated and eluted with water
at a ﬂow rate of 0.11 mLÆmin)1, 3 min per fraction.
Material collected with the inclusion volume of the column
was lyophilized and passed through a Bio-Gel P-4 column
(0.7 · 50 cm) equilibrated and eluted with water at a ﬂow
rate of 0.10 mLÆmin)1, 5 min per fraction, and the high
molecular mass substances, collected with the exclusion
volume, lyophilized and referred to as the N-glycans.
Material collected with the exclusion volume of the
Sephadex G-50 column was lyophilized and submitted to
b-elimination, incubating 40 h at 45 C in 50 mM NaOH
containing 0.5 M sodium borohydride. Unreacted NaBH4
was inactivated with an excess of glacial acetic acid, and
the solution neutralized with NaOH and buffered with
0.1 M ammonium bicarbonate. Total reactions were passed
through a Bio-Gel P-4 column (1.0 · 50 cm), equilibrated
and eluted with water at a ﬂow rate of 0.24 mLÆmin)1,
5 min per fraction. Radioactive material collected with the
inclusion volume of this column was referred to as the
small O-glycans, while the material collected in the ﬂow-
through of the column was lyophilized and passed through
a Sephadex G-50 column (0.7 · 50 cm) equilibrated and
eluted as above. Radioactivity collected with the inclusion
volume, referred to as the large O-glycans, was lyophilized,
resuspended with water at a concentration of 10 000
cpmÆlL)1, and submitted to endo-b-galactosidase digestion
using the enzyme from Bacteriodes fragilis (Sigma E6773),
0.4 mUÆlL)1, for 20 h at 37 C. The reaction mixture was
diluted with water and applied to a QAE-Sephadex
column to separate neutral and charged sugars, according
to a reported procedure [22]. Material collected in the
ﬂow-through was referred to as the neutral fraction, while
that eluted with NaCl, referred to as the acid fraction,
was collected, desalted on a Bio-Gel P-2 column, and
treated with a2,3 sialidase (New England Biolabs P0728)
according to the manufacturer’s recommendations. Neut-
ral and de-sialylated fractions were analysed by a Bio-Gel
P-4 column (0.7 · 100 cm), eluted with water at a ﬂow
rate of 0.06 mLÆmin)1, 6.5 min per fraction. The obtained
peaks were collected, lyophilized, treated with glycohydro-
lases, and submitted to Bio-Gel P-2 chromatography for
characterization [16]. b1,3-galactosidase (New England
Biolabs P0726), a1,3/4-fucosidase (Sigma F-3023), b-N-
acetylhexosaminidase (New England Biolabs P0721), and
b1,4-galactosidase (Sigma G-0413) digestions were per-
formed on radioactive oligosaccharides, 400–1000
c.p.m.ÆlL)1, according to the manufacturer’s recommen-
dations.
Analytical procedures
For transcript quantiﬁcation, competitive RT/PCR was
performed essentially as reported previously [16,20]. First-
strand cDNA was prepared for samples and controls in the
presence or absence of the reverse transcriptase, respectively,
and reactions incubated under the conditions reported [20].
cDNA was ampliﬁed (25 lL reaction volume) in the
presence of 10 fg (glycosyltransferases) or 100 fg (antisense
construct) of the correct competitor for 35 cycles, or in the
presence of 10 pg competitor (b-actin) for 25 cycles, under
the conditions reported [16]. No ampliﬁcation was detected
when the control reactions were used as template. Human
b-actin and b3Gal-T5 competitors and oligonucleotide
primers were those already described [16]. For b3Gal-T5
antisense construct, the competitor was prepared digesting
pEFneo/ASb3Gal-T5 plasmid with PmaCI and Bsp1407I,
blunting the ends, removing the 235-bp fragment, and self
re-ligating the truncated plasmid. The following primers
were used: upper strand primer, 5¢-CCTTCACCATCCT
CTCTTTCCCCCAC-3¢, corresponding to nucleotides 262–
237 of the reverse strand of the b3Gal-T5 coding sequence;
lower strand primer, 5¢-CAGGTTCAGGGGGAGGTGT
GGGAG-3¢, corresponding to nucleotides 31–8 of the
reverse strand of the SV40 polyadenylation signal sequence
of pEFneo vector.
b1,3Gal-T activity was determined in the reported
reaction mixture [16], using 0.6 M GlcNAc as acceptor, in
the presence of cell homogenates at protein concentrations
of 0.5–4.0 mgÆmL)1. Incubations were performed at 37 C
for 60 min.At the end of incubation, reaction products were
assayed by Dowex chromatography and characterized
according to previously reported protocols [18]. In all cases
the reaction product was found to be a disaccharide
sensitive to b1,3galactosidase, as expected. In fact, GlcNAc
is not used as acceptor by b1,4galactosyltransferases under
the reported assay conditions [18,20]. Km calculations were
performed as reported [18].
For dot-blots, 50-lL aliquots of the culture media were
applied to the blotting membrane by vacuum aspiration.
Serial dilution of samples were performed in preliminary
experiments to set the amounts needed for detection.
Membranes were washed, blocked, stained with primary
and peroxidase-labelled secondary antibodies, and visual-
ized by enhanced chemoluminescence as reported for
Western blotting [23]. Monoclonal anti-CEA, anti-sLea
(from hybridoma 1116-NS-19–9), and anti-sLex (from
hybridoma CSLEX1) Igs were as reported [16,20]. Sambu-
cus nigra agglutinin (SNA) staining was preformed as
reported [23].
Results
Construction and characterization of a BxPC3 clone
expressing an antisense b3Gal-T5 fragment
To study the role of b3Gal-T5, we permanently suppressed
the expression in a cell line by an antisense approach. We
chose BxPC3 cells for transfection as they express low
levels of the transcript (0.2 fgÆpg)1 b-actin) but still well
detectable amounts of b1,3Gal-T activity (16.0 nmol
transferred GalÆmg protein)1Æh)1) and sLea, but not Lea,
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Leb or sLex. Moreover, sLea expression in these cells is
affected by benzyl-a-GalNAc but not by swainsonine.
These facts were expected to make the experiment techni-
cally feasible, and the high b1,3Gal-T activity/b3Gal-T5
transcript ratio to provide clear-cut results. Cells were
transfected with a linearized plasmid containing a 553-bp
fragment of b3Gal-T5 cDNA, that includes the initial
360 bp of the coding sequence and 192 bp of the 5¢
untranslated region of the gene, placed in the antisense
orientation under the control of the elongation factor-1a
promoter, and followed by SV40 polyadenylation signals
(Fig. 1). This scheme basically follows the one used
successfully by Hiraiwa et al. for suppressing fucosyltrans-
ferase FucT-VII in lymphoid cells [24]. A cassette for G418
resistance was cotransfected for selection of recombinant
clones. To quantify the levels of the antisense construct
expressed in G418-resistant clones, we used competitive
RT/PCR, taking advantage of primers speciﬁc to such a
construct (Fig. 1). A clone expressing constant high levels
of the antisense construct (60 fgÆpg)1 b-actin) was isolated
and characterized. The clone, named T5AS, retains a low
expression of b3Gal-T5 transcript as in the parental cell
line (Fig. 2A). This indicates that antisense-mediated
mechanism of gene suppression does not involve transcript
synthesis in this case, as already reported [24]. On the other
hand, b1,3Gal-T activity is dramatically reduced and
became faintly detectable in the clone (Fig. 2B). Moreover,
the T5AS clone expresses much less sLea on the cell surface
than BxPC3 cells (Fig. 2C). These data indicate that
b3Gal-T5 is the gene responsible for b1,3Gal-T activity
and sLea antigen synthesis in these cells. In addition, T5AS
clone became weakly positive to sLex, that instead is
undetectable in BxPC3 cells, and remains negative to Lea,
faintly positive to Lex, and moderately positive to SNA, as
are the original BxPC3 cells (Fig. 2C). A relevant amount
of sLex is also found in the culture medium, where sLea,
that is secreted by BxPC3 cells, is almost undetectable.
Characterization of sugar chains synthesized
in the antisense clone
To understand better the consequences of b3Gal-T5
suppression on cell glycosylation, we characterized the
main oligosaccharide chains synthesized by such cells. To
this aim, the antisense clone and parental BxPC3 were
metabolically radiolabelled with tritiated Gal, and the
distribution of radioactivity studied as outlined in Fig. 3.
Table 1 shows that Gal is incorporated into high molecular
mass substances attached to the cell membranes, without
relevant differences between parental cells and antisense
clone. The amount of radioactivity released by N-glycanase
is moderate in both cases, while the bulk of incorporated
Fig. 1. Schematic representation of b3Gal-T5 antisense construct. The
human elongation factor-1a promoter and the SV40 polyadenylation
signal cassettes present in the pEFneo vector are shown together with
the 553-bp fragment ampliﬁed from b3Gal-T5 cDNA, that was cloned
in the antisense orientation using adaptors for the BstXI sites available
in the vector. Numbers in the b3Gal-T5 cassette refer to the cDNA
sequence starting from the ATG translation initiation codon (indica-
ted). Numbers in the SV40 polyadenylation signal cassette refer to the
SV40 sequence in pEFneo vector. The upper strand primer, annealing
to the b3Gal-T5 sequence, and the lower strand primer, annealing to
the SV40 sequence, are also indicated. They were used for RT/PCR
ampliﬁcation of the antisense construct expressed in transfected cells,
and provided a 515-bp ampliﬁcation fragment detected as b3Gal-T5
antisense construct target in Fig. 2A.
Fig. 2. Characterization of T5AS clone. A cell clone expressing a
b3Gal-T5 antisense construct (T5AS) was obtained from the human
pancreatic adenocarcinoma cell line BxPC3. (A) Total RNA was
extracted from BxPC3 cells and T5AS clone, reverse transcribed, and
the ﬁrst-strand cDNA obtained was diluted 1 : 20, v/v, with water.
PCR ampliﬁcations were performed using 0.5-lL aliquots of the
dilutions and primers speciﬁc for human b-actin and antisense con-
struct, respectively, or 5.0 lL of cDNA dilutions and b3Gal-T5 spe-
ciﬁc primers, in the presence of the indicated amounts of the respective
competitor DNAs. Ampliﬁcations were for 25 (b-actin) or 35 cycles
(antisense construct and b3Gal-T5). An aliquot comprising one-ﬁfth of
each PCR reaction was analysed by electrophoresis through a 1%
agarose gel and visualized by staining with ethidium bromide. (B)
b1,3Gal-T activity in BxPC3 cells (j) or in T5AS clone (h) was
determined with GlcNAc as acceptor using diﬀerent amounts of cell
homogenates for a ﬁxed incubation time (1 h), or using a ﬁxed protein
concentration (1.6 mgÆmL)1) for diﬀerent incubation times. (C) Cells
were stained with monoclonal anti-sLea, anti-Lea (both IgG), anti-sLex
and anti-Lex (both IgM) followed by ﬂuorescein-conjugate anti-
mouse IgG or IgM, respectively, or with ﬂuorescein-conjugate
SNA (Sambucus nigra agglutinin) alone, and analysed by ﬂow
cytometry.
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radioactivity is sensitive to b-elimination providing two
fractions: small O-glycans, recovered in the included
volume of the Bio-Gel P4 column, and large O-glycans,
collected with the excluded volume of the Bio-Gel P4 and
the included volume of the Sephadex G-50 column
(Fig. 4B and C). Small O-glycans are present in similar
amounts in BxPC3 and the T5AS clone (Table 1), and to
be mostly constituted by sialylated or neutral disaccharides.
They probably represent core 1 O-glycans that are not
potential substrates of b3Gal-T5 and were not studied
further. Large O-glycans are found in relevant amounts in
both cells. Their size was conﬁrmed by Bio-Gel P-4
chromatography performed in 0.1 M3 acetic acid that shows
that they move between N-glycans and small oligosaccha-
rides (Fig. 4D). Large O-glycans are sensitive to endo-
b-galactosidase treatment, providing neutral (unbound to
QAE-Sephadex) and acid (bound to QAE-Sephadex)
oligosaccharides (Table 1). Neutral oligosaccharides
released by endo-b-galactosidase from BxPC3 large
O-glycans contain a minimal amount of radioactivity and
were not analysed further, whereas those released from
T5AS clone mostly show a disaccharide peak and a smaller
trisaccharide peak (Fig. 4, lower). The disaccharide is
sensitive to b-hexosaminidase, giving rise to radioactive
Gal, and identiﬁed as GlcNAcb1-3Gal. The trisaccharide
was mostly sensitive to b1,4galactosidase, giving rise to a
disaccharide and a monosaccharide, and is thus identiﬁed
as Galb1-4GlcNAcb1-3Gal. The acid fraction of endo-
b-galactosidase sensitive large O-glycans from BxPC3 cells,
upon speciﬁc removal of a2,3 sialyl residues, contains
mostly a tetrasaccharide and a trisaccharide, and an
oligosaccharide peak close to but separated from the void
volume (Fig. 4, lower). The trisaccharide is sensitive to
both b1,3- and b1,4galactosidases, giving rise to a disac-
charide and a monosaccharide, and is thus identiﬁed as a
mixture of Galb1-3GlcNAcb1-3Gal and Galb1-4Glc-
NAcb1-3Gal. The tetrasaccharide is sensitive to a1,3/4
fucosidase giving rise to a trisaccharide that provides equal
amounts of radioactive disaccharide and monosaccharide
upon b1,3galactosidase treatment, and is thus identiﬁed as
Galb1-3[Fuca1-4]GlcNAcb1-3Gal. The acid fraction of
endo-b-galactosidase sensitive O-glycans from the antisense
clone, upon removal of a2,3 sialyl residues, contains mostly
a trisaccharide, a small shoulder corresponding to a
tetrasaccharide, and the oligosaccharides peak separated
from the void volume as well. The trisaccharide was mostly
sensitive to b1,4galactosidase, giving rise to a disaccharide
and a monosaccharide, and is thus identiﬁed as Galb1-
4GlcNAcb1-3Gal, while the tetrasaccharide was sensitive
to a1,3/4 fucosidase, giving rise to a trisaccharide. The
latter was sensitive to both b1,4- and b1,3galactosidases,
giving rise to a disaccharide and a monosaccharide, and
was thus identiﬁed as a mixture of Galb1-4[Fuca1-3]Glc-
NAcb1-3Gal and Galb1-3[Fuca1-4]GlcNAcb1-3Gal. The
calculated amounts of each oligosaccharide are summar-
ized in Table 2. These data indicate that the repression of
b3Gal-T5 reduces the synthesis of type 1 chain carbohy-
drates, including sLea, and enhances that of poly N-acetyl-
lactosamines and sLex on O-glycans. We were unable to
characterize the peak separated from the void volume, but
we believe that it may represent the reducing end of the
sugar chain remaining after endo-b-galactosidase digestion.
Fig. 3. Scheme of sugar chain puriﬁcation. The scheme outlines the
procedure followed for preparing diﬀerent sugar fractions from
metabolically radiolabelled cells. The main fractions obtained are in
boldface, and the more relevant treatments are italicized. The corres-
ponding qualitative results are presented in Fig. 4, and the quantitative
data in Table 1.
Table 1. Radioactivity distribution in BxPC3 cells and T5AS clone
metabolically radiolabelled with [3H]Gal. Values are expressed as
c.p.m. · 106Æmg)1 cell protein.
BxPC3 (%) T5AS (%)
Total cell incorporation 7.40 (100) 7.23 (100)
Glycopeptides 5.92 (80.0) 5.66 (78.2)
N-glycans 0.85 (11.4) 0.74 (10.2)
O-glycans
Small 2.30 (31.1) 2.41 (33.3)
Large 2.24 (30.4) 2.53 (35.1)
Upon endo-b-galactosidase
Unbound to QAE-Sephadex 0.38 (5.1) 0.57 (7.8)
Bound to QAE-Sephadex/
eluted with NaCl
1.12 (15.1) 0.91 (12.5)
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If so, it is interesting to note that the O-glycans carrying
Lewis antigens in BxPC3 appear to be very complex
structures comparable in size to those recently reported in
other cells [25].
Secretion of Lewis antigens in the antisense clone
To assess the effect of b3Gal-T5 repression on the sugar
chains of molecules secreted in the culture media, BxPC3
cells and the antisense clone were cultured and the media
analysed by dot-blot after adding drugs affecting glyco-
sylation. To obtain comparable data, preliminary experi-
ments were performed in order to normalize the amount
of media to be blotted. To this purpose we used CEA as
a reference, as it is secreted by the cells, and stained the
blots with anti-CEA Ig. Fig. 5 shows the results obtained
by staining blots prepared using such amounts of culture
media with anti-sLea and anti-sLex Igs, respectively.
BxPC3 cells secrete sLea in the media but not sLex, while
T5AS clone secretes mostly sLex. Accumulation of both
antigens is prevented by benzyl-a-GalNAc, an inhibitor
of O-glycosylation, while it is not affected by swainso-
nine, an inhibitor of N-glycosylation. These results
conﬁrm that b3Gal-T5 is responsible even for sLea
secreted by the cells, and that O-glycans carried by
secreted molecules are modiﬁed upon b3Gal-T5 repres-
sion in a similar manner as those carried by membrane-
bound molecules.
b1,3Gal-T activity, b3Gal-T5 transcript levels, and sLea
expression in cancer cell lines and recombinant clones
We also measured the levels of b3Gal-T5 transcript and
b1,3Gal-T activity in different cancer cell lines and clones,
and compared them with the amount of sLea antigen
expressed on the cell surface. We found that cells expressing
high levels of transcript, such as COLO-205, SW-1116 or
recombinant HCT-15-T5, express high levels of enzyme
activity; cells expressing lower levels of transcript, such as
CACO-2, HT-29, or BxPC3, express lower b1,3Gal-T
activity levels; while cells not expressing the transcript at all,
such as HCT-15 or Panc-1, have no measurable enzyme
activity (Fig. 6). Surprisingly, the range of b1,3Gal-T
activity/b3Gal-T5 transcript ratio is very broad. The highest
value is found in BxPc3 cells, while it is 16-fold lower in the
HCT-15-T5 clone. To verify that the enzyme activities
measured are due to b3Gal-T5 only, we determined the
enzyme kinetics from representative cells, and found that
the b1,3Gal-T activities detected are kinetically identical to
those of genuine b3Gal-T5. Altogether these data suggest
that b3Gal-T5 regulation is not exclusively transcriptional
in cultured cells, as reported for another glycosyltransferase
[26]. Quantitatively, sLea expression is also roughly corre-
lated with the levels of b3Gal-T5 activity, suggesting that
many factors control antigen expression besides b3Gal-T5
expression. In fact, MKN-45 cells express transcript and
activity but do not express the antigen at all, while a
recombinant clone overexpressing Fuc-TIII, MKN-45-FT,
does express a high amount of antigen. In all cell line sLea
expression is over 90% impaired by benzyl-a-GalNAc
treatment, suggesting an involvement of O-glycans in
carrying the antigen.
Fig. 4. Characterization of radioactive oligosaccharides formed in
metabolically radiolabelled cells. The main radioactive oligosaccharides
formed in BxPC3 cells (j in lower part, andA, B, and C of upper part)
and T5AS clone (h in lower part, and A, B, and C of upper part)
metabolically radiolabelled with [3H]Gal were characterized. Upper
part: cell lysates were treated with N-glycanase and passed through a
Sephadex G-50 column (A) and the material collected with the ﬂow-
through of the column (horizontal bar) was submitted to b-elimin-
ation. Upon b-elimination the material was passed through a Bio-Gel
P-4 column (B), and the material collected with the excluded volume of
the column (horizontal bar) was passed again through a Sephadex
G-50 column (C). Material included in this last column (horizontal
bar) represents large O-glycans. (D) N-glycans (h), obtained by Bio-
Gel P-4 puriﬁcation of the included volume of the column in (A), large
O-glycans (j), obtained as the included volume of the column in (C),
and small O-glycans (s), obtained as the included volume of the col-
umn in (B), were analysed by a Bio-Gel P-4 column equilibrated and
eluted with 0.1 M acetic5 acid. The proﬁles obtainedwith the radioactive
fractions prepared from BxPC3 cells are presented, those obtained
with fractions from T5AS clone were identical. Lower part: large
O-glycans were treated with endo-b-galactosidase and passed through
a QAE-Sephadex column. Radioactivity not bound to QAE-Sephadex
was lyophilized and applied directly to a long Bio-Gel P4 column
(neutral fraction), while radioactivity bound to QAE-Sephadex and
eluted with NaCl was desalted, treated with a2,3 sialidase, and then
applied to the column (acid fraction). Column calibration is shown at
the top.
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Discussion
We have found that b3Gal-T5 is responsible for sLea
antigen synthesized on O-glycans expressed on or secreted
by an epithelial cell line, whereas antisense-mediated
suppression of the enzyme turns synthesis of O-glycans to
poly N-acetyllactosamine elongation and termination by
sLex. Taken together with our previous data on b3Gal-T5
downregulation in colon cancer andN-glycan synthesis [16],
the results suggest that b3Gal-T5 may play a protective role
in gastrointestinal and pancreatic cells, counteracting the
glycosylation pattern associated to malignancy.
We found in fact that NeuAca2-3Galb1-3[Fuca1-4]Glc-
NAcb1-3Gal and NeuAca2-3Galb1-3GlcNAcb1-3Gal are
the main oligosaccharides released by endo-b-galactosidase
treatment of large O-glycans in BxPC3 cells, while in the
clonewhereb3Gal-T5 is suppressed they aremostly replaced
by poly N-acetyllactosamine units differently substituted by
sialic acid and fucose. The levels of a1,3 fucosylation and
sLex expression were rather low in this case, probably
because BxPC3 cells express Fuc-TIII but almost no pure
a1,3fucosyltransferase [27], including Fuc-TVII that is not
expressed in any cell line used in the present study [27–29].
However,moderate amounts of sLexwere recently proved to
be the most efﬁcient in promoting metastatic spread [30].
These data match the ﬁnding that CEA synthesized by
normal mucosa has abundant N-linked type 1 chains due to
b3Gal-T5 activity, and that are replaced by poly N-acetyl-
lactosamines in cancer where the enzyme is downregulated
[16,31]. Altogether they suggest that b3Gal-T5 synthesizes
type 1 chains that do prevent poly N-acetyllactosamine
elongation and sLex synthesis on both N- and O-glycans.
Due to the involvement of such structures in malignancy,
b3Gal-T5 regulation may play an important role in colon
cancer, as the residual expression levelpotentially contributes
to prevention of the malignant phenotype.
Synthesis and expression of sLea is a relevant issue per se,
as it is the epitopeof theCA19.9 antigen, sometimes found to
be elevated in the serum of patients with various abdominal
illnesses [32] including cancers of the digestive tract [33–35].
Moreover, it is an E-selectin ligand [36] andmay be involved
in themetastatic spread of cancer cells, as suggested for other
selectin ligands [37]. Previous data indicate that b3Gal-T5 is
the enzyme candidate for synthesis of sLea [15–18], but the
ﬁnding that sLea is strongly expressed in normal mucosa
Fig. 6. Expression of b3Gal-T5 and sLea in diﬀerent cells.Diﬀerent cell
lines and clones were cultured, harvested, and analysed as follows.
b3Gal-T5 transcript (ﬁlled bars) was quantiﬁed by competitive RT/
PCR starting fromRNA extracted from aliquots of the cell pellets, and
b3Gal-T5 activity (empty bars) was determined by in vitro assay using
homogenates prepared from a second aliquot of the cell pellet. sLea
antigen expressed on the cell surface (grey bars) was determined by
immunostaining and ﬂow cytometry performed on a fresh aliquot of
the cell pellet. Results are expressed as relative values, 100% corres-
ponds to 18 fgÆpg)1 b-actin for transcripts, to 190 ng of transferred
GalÆmg)1 homogenate proteinÆh)1 for enzyme activity, and to
50 arbitrary units for ﬂuorescence.
Table 2. Main oligosaccharides released from BxPC3 cells and T5AS clone by endo-b-galactosidase treatment of metabolically labelled O-glycans.
Values are expressed as c.p.m. · 103Æmg)1 cell protein.
BxPC3 T5AS
GlcNAcb1-3Gal <0.5 8.8
Galb1-4GlcNAcb1-3Gal <0.5 3.1
NeuAca2-3Galb1-4GlcNAcb1-3Gal 2.1 12
NeuAca2-3Galb1-4[Fuca1-3]GlcNAcb1-3Gal <0.1 1.4
NeuAca2-3Galb1-3GlcNAcb1-3Gal 5.2 1.7
NeuAca2-3Galb1-3[Fuca1-4]GlcNAcb1-3Gal 10 0.9
Fig. 5. Secretion of Lewis antigens in the culture medium of BxPC3 cells
and T5AS clone. Cells were grown under regular conditions for 30 h
before treatment, then the tissue culture media were collected and
replaced with fresh regular media alone (controls), or containing
1.0 lgÆmL)1 swainsonine or 2 mM benzyl-a-GalNAc. Media were
collected again 60 h after treatment. Aliquots of collected media,
normalized with respect to the amount of secreted CEA, were blotted
and stained with primary anti-sLea or anti-sLex Igs followed by per-
oxidase-labelled secondary antibody.
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makes this open to question.4 Here we found evidence that
b3Gal-T5 is actually necessary for sLea synthesis on
O-glycans in gastrointestinal and pancreatic cells. In fact, in
BxPC3 cells antisense suppression of the gene dramatically
reduces b1,3Gal-T activity as well sLea antigen expression
and secretion.Moreover, only cell lines expressing b3Gal-T5
express the antigen, and cells not expressing are forced to do
bycDNAtransfection.Ontheotherhand, sLea synthesis and
secretion appear to depend on multiple molecular or
enzymatic mechanisms. We speculate they may include
several interacting factors such as the nature and availability
of substrates, includingnucleotide sugars [38], thepresenceof
other cooperative or competing enzymes [39], as well their
sub-Golgi localization [40]. Our working hypothesis is that
the biological role of b3Gal-T5 includes, but is not restricted
to, sLea synthesis, that probably requires several concurrent
factors in vivo. Phylogenetic observations agree with this
concept. In fact, while a1,4 fucosylation and thus sLea
synthesis are recent evolutionary acquisitions belonging to
humans and someprimates [41],b3Gal-T5 is present inother
mammals such as mice [42], rats (GenBank accession
XM221525), and very probably pigs [43]. While this manu-
script was being completed, Isshiki et al. reported that
b3Gal-T5 is transcriptionally regulated by homeoproteins
speciﬁc to the intestinal mucosa [44]. They also found that
some of these homeoproteins, as well as b3Gal-T5, are
upregulated during CACO-2 cell differentiation and down-
regulated in colon cancer, but that b3Gal-T5 protein is not
correlatedwith the amount ofCA19.9 in cancer tissues. Such
results elegantly show that type 1 chain carbohydrates are
products of b3Gal-T5 activity as a part of the speciﬁc
phenotype of the normal intestinal mucosa. Taken together
withourprevious [16] andpresentﬁndings, andwith thoseon
CACO-2 differentiation [13,14], they corroborate the hypo-
thesis that b3GalT-5 and type 1 chain carbohydrates are
markersof normal glycosylation in epithelia of the digestive
tract. In this context, the use of CA19.9 antigen as a tumour
markerappearsparadoxical, since it is aproductofb3Gal-T5
activity on type 1 chain O-glycans. We believe that further
studies are needed to elucidate the metabolic origin of
CA19.9 circulating in patients and to conﬁrm the actual
ability of gastrointestinal and pancreatic cancers to synthes-
ize and secrete large amounts of sLea.
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